

**TRADEMARK ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST

**CONVEYING PARTY DATA**

Name	Formerly	Execution Date	Entity Type
Sagent Pharmaceuticals, Inc.		09/26/2011	CORPORATION: DELAWARE

**RECEIVING PARTY DATA**

<b>Name:</b>	MidCap Funding IV, LLC, as Agent
<b>Street Address:</b>	7255 Woodmont Avenue
<b>Internal Address:</b>	Suite 200
<b>City:</b>	Bethesda
<b>State/Country:</b>	MARYLAND
<b>Postal Code:</b>	20814
<b>Entity Type:</b>	LIMITED LIABILITY COMPANY: DELAWARE

**PROPERTY NUMBERS Total: 15**

Property Type	Number	Word Mark
Serial Number:	78867342	SAGENT PHARMACEUTICALS
Serial Number:	77256646	INJECTABLES EXCELLENCE
Serial Number:	77256647	ADVANCE INJECTABLES EXCELLENCE
Serial Number:	77256654	CREATE INJECTABLES EXCELLENCE
Serial Number:	77256656	DISCOVER INJECTABLES EXCELLENCE
Serial Number:	77256659	INVEST IN INJECTABLES EXCELLENCE
Serial Number:	77256745	SSS
Serial Number:	77256750	SAGENT
Serial Number:	77256642	SAGENT PHARMA
Serial Number:	77969951	REVOLO
Registration Number:	3743423	SAGENT PHARMACEUTICALS
Registration Number:	3952285	ANECLEAR
Registration Number:	3959638	ANECLEAR

CH \$390.00 78867342

Registration Number:	3952489	ANECLEAR
Registration Number:	3729987	SSS

**CORRESPONDENCE DATA**

Fax Number: (312)609-5005  
Phone: (312) 609-7838  
Email: podonoghue@vedderprice.com  
*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.*  
Correspondent Name: Patricia O'Donoghue, Vedder Price P.C.  
Address Line 1: 222 North LaSalle Street  
Address Line 2: Suite 2500  
Address Line 4: Chicago, ILLINOIS 60601

ATTORNEY DOCKET NUMBER:	41012.00.0013
NAME OF SUBMITTER:	Patricia O'Donoghue
Signature:	/Patricia O'Donoghue/
Date:	09/27/2011

**Total Attachments: 11**  
source=Sagent Pharmaceuticals Inc. Trademark Security Agreement#page1.tif  
source=Sagent Pharmaceuticals Inc. Trademark Security Agreement#page2.tif  
source=Sagent Pharmaceuticals Inc. Trademark Security Agreement#page3.tif  
source=Sagent Pharmaceuticals Inc. Trademark Security Agreement#page4.tif  
source=Sagent Pharmaceuticals Inc. Trademark Security Agreement#page5.tif  
source=Sagent Pharmaceuticals Inc. Trademark Security Agreement#page6.tif  
source=Sagent Pharmaceuticals Inc. Trademark Security Agreement#page7.tif  
source=Sagent Pharmaceuticals Inc. Trademark Security Agreement#page8.tif  
source=Sagent Pharmaceuticals Inc. Trademark Security Agreement#page9.tif  
source=Sagent Pharmaceuticals Inc. Trademark Security Agreement#page10.tif  
source=Sagent Pharmaceuticals Inc. Trademark Security Agreement#page11.tif

## TRADEMARK SECURITY AGREEMENT

**THIS TRADEMARK SECURITY AGREEMENT** (the "Agreement") made as of this 26th day of September, 2011, by **SAGENT PHARMACEUTICALS, INC.**, a Delaware corporation ("Grantor"), in favor of **MIDCAP FUNDING IV, LLC**, in its capacity as Agent for the Lenders party to the Credit Agreement (defined below) (together with its successors and assigns, "Grantee"):

### W I T N E S S E T H:

**WHEREAS**, Grantor, Grantee and Lenders are parties to that certain Credit and Security Agreement dated June 16, 2009 (as the same may be amended, restated, supplemented, or otherwise modified from time to time, the "Credit Agreement"), providing for extension of a term loan to be made to Grantor by Lenders; and

**WHEREAS**, pursuant to the terms of the Credit Agreement and certain other Security Documents now and/or hereafter executed by Grantor in favor of Grantee, Grantor has granted to Grantee, for the benefit of Lenders, a security interest in substantially all of the assets of Grantor including all right, title and interest of Grantor in, to and under all now owned and hereafter acquired: (i) all trademarks, trade names, corporate names, company names, business names, fictitious business names, trade styles, service marks, logos and other source or business identifiers, and the goodwill associated therewith, now existing or hereafter adopted or acquired, all registrations and recordings thereof, and all applications in connection therewith (other than "intent to use" applications until a verified statement of use is filed with respect to such applications), whether in the United States Patent and Trademark Office or in any similar office or agency of the United States, any state thereof or any other country or any political subdivision thereof, or otherwise and (ii) all renewals thereof ((i) and (ii), collectively, "Trademarks"), (iii) any agreement, written or oral, providing for the grant by or to a Grantor of any right to use any Trademark (collectively, the "Trademark Licenses"), (iv) the goodwill of the business symbolized by Grantor's Trademarks, and (v) all products and proceeds thereof, to secure the payment of all amounts owing by Grantor and the other Borrowers under the Credit Agreement;

**NOW, THEREFORE**, in consideration of the premises set forth herein and for other good and valuable consideration, receipt and sufficiency of which are hereby acknowledged, Grantor agrees as follows:

1. Incorporation of Credit Agreement and Security Documents. The Credit Agreement and the Security Documents and the terms and provisions thereof are hereby incorporated herein in their entirety by this reference thereto. All terms capitalized but not otherwise defined herein shall have the same meanings herein as in the Credit Agreement.

2. Grant and Reaffirmation of Grant of Security Interests. To secure the payment and performance of the Obligations, and without limiting any other grant of any security interest or lien in any assets of Grantor provided for or created under any other Security Document, Grantor hereby grants to Grantee, for its benefit and the benefit of Lenders, and hereby reaffirms its prior grant pursuant to the Credit Agreement and the other Security Documents of, a continuing security interest in Grantor's entire right, title and interest in and to the following (all

of the following items or types of property being herein collectively referred to as the "Trademark Collateral"), whether now owned or existing and hereafter created, acquired or arising:

(i) each Trademark License and Trademark listed on Schedule 1 annexed hereto, together with any reissues, continuations or extensions thereof, and all of the goodwill of the business connected with the use of, and symbolized by, each Trademark; and

(ii) all products and proceeds of the forgoing, including without limitation, any claim by Grantor against third parties for past, present or future (a) infringement or dilution of any Trademark, or (b) injury to the goodwill associated with any Trademark.

3. Agreement to Deliver Supplements. Grantor hereby covenants and agrees that, in connection with the delivery by Grantor of the Compliance Certificate required to be delivered by Grantor under Section 4.1 of the Credit Agreement in connection with the financial statements of Grantor and its affiliates, Grantor shall (i) provide Grantee a listing of any new Trademark or Trademark License (including any new trademark application and any new trademark registered with respect to any trademark application previously listed on Schedule 1 hereto or on Schedule A to any other supplement delivered to Grantee in accordance with this paragraph, "New Trademarks") acquired during the fiscal quarter corresponding to such financial statement and (ii) deliver to Grantee a duly executed supplement to this Agreement in the form of Exhibit A hereto, listing all such New Trademarks on Schedule A thereto, pursuant to which Grantor shall grant and reconfirm the grant of a security interest in such New Trademarks and the proceeds thereof to Grantee to secure the Obligations, which such supplement may be and is intended by the parties to be filed with the United States Patent and Trademark Office.

4. Representations and Warranties. Grantor hereby represents and warrants to Grantee and to the Lenders that Schedule 1 sets forth a full, complete and correct list of all issued Trademarks and pending trademark applications, owned by Grantor as of the date hereof.

5. Events of Default and Remedies. Upon the occurrence of and during the continuance of any Event of Default, Grantee, in addition to all other rights, options, and remedies granted to Grantee under the Credit Agreement or any other Security Document, or otherwise available to Grantee at law or in equity, may exercise, either directly or through one or more assignees or designees, with respect to the Trademark Collateral all rights and remedies granted to it as a secured creditor under the Uniform Commercial Code as in effect in the State of Maryland from time to time.

6. Governing Law. THIS AGREEMENT AND ALL MATTERS RELATING HERETO OR ARISING HEREFROM (WHETHER SOUNDING IN CONTRACT LAW, TORT LAW OR OTHERWISE), SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF MARYLAND, WITHOUT REGARD TO CONFLICTS OF LAWS PRINCIPLES.


*(Signature Pages Follow)*

*(Signature Page to Trademark Security Agreement)*

**IN WITNESS WHEREOF**, intending to be legally bound, Grantor has duly executed this Trademark Security Agreement as of the day and year first hereinabove set forth.

**GRANTOR:**

**SAGENT PHARMACEUTICALS, INC.**, a  
Delaware corporation

By: \_\_\_\_\_   
Jonathon Singer  
Chief Financial Officer

*(Signature Page to Trademark Security Agreement)*

Agreed and Accepted  
As of the Date First Written Above

**GRANTEE:**

**MIDCAP FUNDING IV, LLC**, a Delaware  
limited liability company, as Administrative  
Agent and Grantee

By: 

Brett Robinson  
Managing Director

## Schedule 1

### Trademark Applications

<b>Trademark/Service Mark</b>	<b>Serial Number</b>	<b>Filing Date</b>	<b>Goods/Services</b>
Sagent Pharmaceuticals (standard characters)	78867342	Apr. 21, 2006	Pharmaceuticals (broader); prefilled syringes; safety syringe devices; drug delivery systems
Sagent Pharmaceuticals (standard characters)	78867342	Apr. 21, 2006	Pharmaceuticals (broader); prefilled syringes; safety syringe devices; drug delivery systems
Injectables Excellence (standard characters)	77256646	Aug. 30, 2006	Pharmaceuticals; pre-filled syringes; safety syringe devices, etc.
Advance Injectables Excellence (standard characters)	77256647	Aug. 16, 2007	Pharmaceuticals; pre-filled syringes; safety syringe devices, etc.
Create Injectables Excellence (standard characters)	77256654	Aug. 16, 2007	Pharmaceuticals; pre-filled syringes; safety syringe devices, etc.
Discover Injectables Excellence (standard characters)	77256656	Aug. 16, 2007	Pharmaceuticals; pre-filled syringes; safety syringe devices, etc.
Invest In Injectables Excellence (standard characters)	#77256659	Aug. 16, 2007	Pharmaceuticals; pre-filled syringes; safety syringe devices, etc.
“SSS” (Design/Logo)	#77256745	Aug. 16, 2007	Pharmaceuticals; pre-filled syringes; safety syringe devices, etc.
Sagent (standard characters)	#77256750	Aug. 16, 2007	Pharmaceuticals; pre-filled syringes; safety syringe devices, etc.

Sagent Pharma (standard characters)	77256642	Aug. 16, 2007	Pharmaceuticals; pre-filled syringes; safety syringe devices, etc.
Revolon (standard characters)	#77969951	Mar. 26, 2010	An anesthetic gas absorber sold as a component of a finished medical device for use in reducing the effects of inhaled volatile anesthetics

### Trademarks

Trademark/Service Mark	Registration Number	Registration Date	Goods/Services
Sagent Pharmaceuticals (standard characters)	3743423	Jan. 26, 2010	Pharmaceuticals; Injectable Drugs
Aneclear (standard characters)	3952285	Apr. 26, 2011	A medical device for reducing the effects of inhaled volatile anesthetics
Aneclear (Design/Logo)	3959638	May 10, 2011	A medical device for reducing the effects of inhaled volatile anesthetics
Aneclear (Design/Logo)	3952489	April 26, 2011	A medical device for reducing the effects of inhaled volatile anesthetics
"SSS" (Design/Logo)	3729987	Dec. 22, 2009	Pharmaceuticals, namely, anti- infectives, antiemetics, oncolytics; pre- filled syringes



**EXHIBIT A**

**SUPPLEMENT TO TRADEMARK SECURITY AGREEMENT**

**THIS SUPPLEMENT TO TRADEMARK SECURITY AGREEMENT** (the "Supplement") made as of this \_\_\_ day of \_\_\_\_\_, 201\_\_ by **SAGENT PHARMACEUTICALS, INC.**, a Delaware corporation (the "Grantor"), in favor of **MIDCAP FUNDING IV, LLC**, a Delaware limited liability company, in its capacity as Agent for the Lenders party to the Credit Agreement (as defined in the Trademark Agreement) (together with its successors and assigns, "Grantee");

W I T N E S S E T H:

**WHEREAS**, Grantor, Grantee and certain financial institutions are parties to that certain Credit and Security Agreement dated as of June 16, 2009 (as the same heretofore may have been and hereafter may be amended, restated, supplemented or otherwise modified from time to time, the "Credit Agreement");

**WHEREAS**, Grantor and Grantee are parties to a certain Trademark Security Agreement dated as of September 26, 2011 (as the same heretofore may have been and hereafter may be amended, restated, supplemented or otherwise modified from time to time, the "Trademark Agreement"); capitalized terms used herein but not otherwise defined shall have the meanings given thereto in the Trademark Agreement);

**WHEREAS**, pursuant to the terms of the Trademark Agreement, Grantor has granted to Grantee to secure the Obligations a security interest in and to all of Grantor's now existing and hereafter New Trademarks and all proceeds thereof; and

**WHEREAS**, also pursuant to the Trademark Agreement, Grantor has agreed that in connection with the acquisition by Grantor of any New Trademarks, Grantor shall deliver to Grantee a Supplement to the Trademark Agreement in the form of Exhibit A to such Trademark Agreement pursuant to which Grantor shall grant and reconfirm the grant by them of a security interest in all such New Trademarks and the proceeds thereof, which such Supplement may be and is intended by the parties to be filed with the United States Trademark Office.

**NOW, THEREFORE**, in consideration of the premises set forth herein and for other good and valuable consideration, receipt and sufficiency of which are hereby acknowledged, and with the foregoing background and recitals incorporated by reference, Grantor agrees as follows:

(i) 1. Grant and Reaffirmation of Grant of Security Interests. To secure the payment and performance of the Obligations, and without limiting any other grant of any security interest or lien in any assets of Grantor provided for or created under the Credit Agreement or any other Security Document, Grantor hereby grants to Grantee, for its benefit and the benefit of the Lenders, and hereby reaffirms its prior grant pursuant to the Credit Agreement and the other Security Documents, specifically including the Trademark Agreement of, a continuing security interest in Grantor's entire right, title and interest in and to the New Trademarks listed on Schedule A to this Supplement, including any reissues, continuations or extensions thereof, and all of the goodwill of the business connected with the use of, and

symbolized by, each Trademark, and all products and proceeds of the forgoing, including without limitation, any claim by Grantor against third parties for past, present or future (a) infringement or dilution of any Trademark, or (b) injury to the goodwill associated with any Trademark, and agrees that all such New Trademarks and the proceeds thereof shall be included in and be part of the Trademark Collateral and otherwise subject to all of the terms and provisions of the Trademark Agreement.

2. Representations and Warranties. Grantor hereby represents and warrants to Grantee and to the Lenders that Schedule A sets forth a full, complete and correct list of all issued New Trademarks and pending applications for Trademarks owned by Grantor as of the date hereof that were not (i) listed on the Schedule 1 delivered in connection with the original Trademark Agreement or (ii) listed on the Schedule A delivered in connection with any Supplement to the Trademark Agreement delivered by Grantor to Grantee prior to the date hereof.

3. Incorporation of the Trademark Agreement. The terms and provisions of the Trademark Agreement are hereby incorporated by reference and this Supplement shall be considered an amendment and supplement to and part of the Trademark Agreement, all of the provisions of which Trademark Agreement are and remain in full force and effect. Any reference after the date hereof in any Financing Document to the Trademark Agreement shall be a reference to the Trademark Agreement as amended and supplemented by this Supplement.

4. Governing Law. THIS SUPPLEMENT AND ALL MATTERS RELATING HERETO OR ARISING HEREFROM (WHETHER SOUNDING IN CONTRACT LAW, TORT LAW OR OTHERWISE), SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF MARYLAND, WITHOUT REGARD TO CONFLICTS OF LAWS PRINCIPLES.

*[Signatures on Following Page]*

*(Signature Page to Supplement to Trademark Security Agreement)*

**IN WITNESS WHEREOF**, intending to be legally bound, the undersigned have duly executed this Supplement to the Trademark Security Agreement as of the day and year first hereinabove set forth.

**GRANTOR:**

**SAGENT PHARMACEUTICALS, INC.**,  
a Delaware corporation

By: \_\_\_\_\_  
Jonathon Singer  
Chief Financial Officer

*(Signature Page to Supplement to the Trademark Security Agreement)*

Agreed and Accepted

As of the Date First Written Above

**GRANTEE:**

**MIDCAP FUNDING IV, LLC**, a Delaware  
limited liability company, as Grantee and  
Administrative Agent

By: \_\_\_\_\_  
Name: \_\_\_\_\_  
Title: \_\_\_\_\_

*(Signature Page to Supplement to the Trademark Security Agreement)*

**SCHEDULE A TO SUPPLEMENT TO TRADEMARK SECURITY AGREEMENT  
DATED \_\_\_\_\_**

**Trademark Applications**

<b>Trademark/Service Mark</b>	<b>Serial Number</b>	<b>Filing Date</b>	<b>Goods/Services</b>

**Trademarks**

<b>Trademark/Service Mark</b>	<b>Registration Number</b>	<b>Registration Date</b>	<b>Goods/Services</b>